Why the study?
Whether cerebral small vessel disease burden differs between warfarin-associated and DOAC-associated intracerebral hemorrhage remains unclear.
Does cerebral small vessel disease burden differ between DOAC-associated, warfarin-associated, and non-anticoagulant-associated spontaneous intracerebral hemorrhage?
Population
Consecutive patients aged ≥20 years admitted for spontaneous ICH
Comparison
DOAC users vs warfarin users vs matched AC non-users
Design
Prospective cohort study
Key result
Warfarin users who experienced intracerebral hemorrhage demonstrated a significantly lower small vessel disease burden compared with DOAC users (cOR 0.22) and anticoagulant non-users.
Authors
Loading...
Does not alter anticoagulation decisions in ICH; leaves open whether SVD burden differs by prior anticoagulant type.
Cohort (n=384)
No
Does cerebral small vessel disease burden differ between DOAC-associated, warfarin-associated, and non-anticoagulant-associated spontaneous intracerebral hemorrhage?
Effect estimate: cOR 0.22 (95% CI 0.10-0.48)
Absolute Event Rate: 0% vs 2%
p-value: p=<0.001
This study investigates whether the burden of cerebral small vessel disease differs among patients presenting with spontaneous intracerebral hemorrhage who were previously treated with DOACs, warfarin, or no anticoagulation.
Tang et al. (2026) conducted a cohort in Spontaneous intracerebral hemorrhage (n=384). Warfarin vs. Direct oral anticoagulants (DOAC) and anticoagulant non-users was evaluated on CT-evaluated small vessel disease (CT-SVD) burden score (cOR 0.22, 95% CI 0.10-0.48, p=<0.001). Warfarin users who experienced intracerebral hemorrhage demonstrated a significantly lower small vessel disease burden compared with DOAC users (cOR 0.22) and anticoagulant non-users.